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Abstract
Background:  In women with breast cancer submitted to neoadjuvant chemotherapy based in
doxorubicin, tumor expression of groups of three genes (PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1,
SMYD2) have classified them as responsive or resistant. We have investigated whether expression of these
trios of genes could predict mammary carcinoma response in dogs and whether tumor slices, which
maintain epithelial-mesenchymal interactions, could be used to evaluate drug response in vitro.
Methods: Tumors from 38 dogs were sliced and cultured with or without doxorubicin 1 μM for 24 h.
Tumor cells were counted by two observers to establish a percentage variation in cell number, between
slices. Based on these results, a reduction in cell number between treated and control samples ≥ 21.7%,
arbitrarily classified samples, as drug responsive. Tumor expression of PRSS11, MTSS1, CLPTM1 and
SMYD2, was evaluated by real time PCR. Relative expression results were then transformed to their
natural logarithm values, which were spatially disposed according to the expression of trios of genes,
comprising PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2. Fisher linear discrimination test was
used to generate a separation plane between responsive and non-responsive tumors.
Results: Culture of tumor slices for 24 h was feasible. Nine samples were considered responsive and 29
non-responsive to doxorubicin, considering the pre-established cut-off value of cell number reduction ≥
21.7%, between doxorubicin treated and control samples. Relative gene expression was evaluated and
tumor samples were then spatially distributed according to the expression of the trios of genes: PRSS11,
MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2. A separation plane was generated. However, no clear
separation between responsive and non-responsive samples could be observed.
Conclusion: Three-dimensional distribution of samples according to the expression of the trios of genes
PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 could not predict doxorubicin in vitro
responsiveness. Short term culture of mammary gland cancer slices may be an interesting model to
evaluate chemotherapy activity.
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Introduction
Human and canine malignant mammary tumors share
some epidemiological and clinicopathological features.
Incidence in both species increases with age, lifetime
exposure to endogenous or exogenous estrogens is a com-
mon risk factor, and the majority of malignant mammary
gland tumors arises from epithelial tissue [1-3]. In addi-
tion, some prognostic factors are similar for both species,
such as clinical stage, tumor size, histological type and
grade, however adjacent lymph node involvement is still
a matter of discussion [1,4-7]. Furthermore, estrogen
receptor expression, proliferation index evaluated by
PCNA, Ki67 expression, or S-phase rate, have also been
correlated to prognosis in canine mammary tumors [5,6],
and immunohistochemical detection of Bcl2, p53 and
cytokeratins, in human and canine tumors and corre-
sponding adjacent tissues, have been similar [8].
In dogs, standard treatment for mammary gland cancer is
surgical excision however, chemotherapy recommenda-
tion, as well as in women, is based on some prognostic
factors. Furthermore, clinical information available in vet-
erinary medicine suggests that drugs that are effective in
human breast cancer, such as doxorubicin, cyclophospha-
mide, 5-fluorouracil and taxanes, may play a role in the
treatment of malignant mammary gland tumors in dogs
[2,9-12].
In women, neoadjuvant chemotherapy for breast cancer is
associated with the same survival benefit as adjuvant
chemotherapy and offers the advantage of an increased
likelihood of breast conservation. Many drug regimens
have been used for a varied number of cycles and two of
the most used drugs, doxorubicin and cyclophosphamide,
when given before surgery are associated with 49–85%
response rates [13-15].
Another potential benefit of neoadjuvant chemotherapy
may be the opportunity of in vivo assessment of tumor
response and the possibility of determination of potential
predictive factors, which may influence clinical decision
making in the future. However, this potential has yet to be
fulfilled, and although predictive factors might help selec-
tion of the appropriate treatment for each individual
patient, to date, there is no single marker with a predictive
value for a patient's response to chemotherapy [16].
We have previously conducted a study to identify predic-
tive markers of response to neoadjuvant chemotherapy
based on doxorubicin. Forty-four breast cancer patients
submitted to neoadjuvant chemotherapy (doxorubicin
and cyclophosphamide, AC, for four cycles, each 21 days)
had tumor samples collected before treatment. Response
was evaluated by palpation of the breast tumor and axil-
lary lymph nodes, before and after chemotherapy, and a
reduction of at least 30% in tumor dimension was classi-
fied as a partial response, according to RECIST criteria
[17]. Following these criteria, 35 and nine patients pre-
sented a responsive and a resistant disease, respectively.
Tumor gene expression was evaluated by cDNA microar-
rays and a differential profile between responsive and
non-responsive patients, was determined. In addition, an
extensive search was done in order to select trios of genes,
whose expression could separate the responsive versus
non-responsive tumors. One such trio genes was PRSS11
(Protease, Serine, 11), MTSS1 (Metastasis Suppressor 1),
and CLPTM1 (Cleft Lip- and Palate-Associated Trans-
membrane Protein 1), which could correctly classify 95%
of the samples, and another one, was PRSS11, MTSS1, and
SMYD2 (Set and Mynd Domain-Containing Protein 2)
[18].
Our present aim was to evaluate whether expression of
these trios of genes could also predict drug response in
another animal species. However, neoadjuvant chemo-
therapy is not routinely administered to dogs, as mam-
mary gland conservation is of limited value. An option
would be to analyze tumor response to chemotherapy in
vitro.
Increasing evidence indicates that tumor cell behavior
depends upon dynamic interactions between epithelial
tumor cells and their microenvironment, including stro-
mal cells and extracellular matrix. In addition, breast can-
cer tissue maintained in short term culture was previously
shown as a potential model to study the activity of drugs
(i.e. paclitaxel) and hormones (i.e. estrogen and calcitriol)
[19-22]. Hence, we have also examined whether response
to chemotherapy could be evaluated in mammary carci-
noma from dogs when cultured as tissue slices.
Our data indicate that expression of these two trios of
genes is not associated with canine mammary carcinoma
response to doxorubicin, however, tumor slices culture
may be an interesting model to evaluate drug response in
vitro.
Methods
Tumor samples were obtained from 38 dogs undergoing
mastectomy at the "Hospital da Faculdade de Medicina
Veterinária da Universidade Metodista de São Paulo
(UMESP)", São Bernardo do Campo, SP, Brazil, from
March 2005 to January 2006. This study was approved by
the Institutional Ethics Committee and animal owners
signed the informed consent. Median age of patients was
10.4 y and 55% and 18.4% of them were mixed and poo-
dle breeds, respectively. Eight patients were previously
spayed.Acta Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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Patients were evaluated by clinical history and physical
examination including mammary tumor measurement
and inguinal and axillary nodes palpation, performed by
two veterinarians. Regional lymph nodes were dissected
during surgery and submitted to histological examina-
tion. Thoracic radiographs (ventrodorsal, right-to-left and
left-to-right lateral projections) were performed to detect
pulmonary metastasis. Patients were classified in clinical
stage III (39.4%), II (28.9%), I (18.4%) and IV (13.1%)
(pulmonary metastasis only) [23].
After histological examination of the surgical specimens
by a veterinary pathologist, only samples of infiltrating
carcinoma were selected for RT-PCR analysis. Carcinomas
were classified as complex (WHO class 1.2) or simple
(WHO class 1.3), including tubulopapillary (tubular,
papillary, or papillary-cystic types), solid and anaplastic
carcinomas [24]. The most frequently histological type
observed was tubullopapillary (tubular and cystic-papil-
lary, 34.2% and 28,9%, respectively) (Table 1). No ana-
plastic carcinomas were detected. Tumors were mainly of
low histological grade.
Fragments of approximately 10 mm wide × 20 mm long,
from small as well as from bulky tumors, were collected
just after surgery by tumor incision and placed into cul-
ture medium (DMEM with antibiotics and fungicide) for
transportation. Fragments were further cut in consecutive
Table 1: Characteristics of patients.
Patient Age (y) Breed Previously spayed T N M Clinical stage Tumor type Histological Grade
1 12 Mixed breed Yes 3 (-) 0 III TPC (PC) I
2 8 Doberman Pinscher No 3 (-) 1 IV TPC (TC) I
3 12 German Shepherd No 3 (-) 0 III TPC (TC) III
4 13 Belgian Shepherd No 3 (-) 0 III CC II
5 13 Mixed breed No 1 (-) 0 I TPC (TC) I
6 8 Napolitan mastiff No 1 (-) 0 I TPC (TC) I
7 12 Poodle No 2 (-) 0 II TPC (CPC) I
8 10 Mixed breed No 3 (-) 0 III TPC (CPC) II
9 11 Mixed breed No 2 (-) 0 II TPC (CPC) I
10 7 Akita No 3 (-) x III TPC (CPC) I
11 11 Akita No 3 (-) 0 III TPC (TC) II
12 9 Mixed breed No 2 (-) 0 II TPC (TC) II
13 15 Mixed breed No 2 (-) 0 II SC II
14 13 Mixed breed No 1 (-) 0 I TPC II
15 6 Mixed breed No 3 (-) 0 III SC ND
16 12 Dachshund No 3 (-) 0 III SC ND
17 10 Poodle Yes 1 (-) 0 I TPC (TC) ND
18 12 Mixed breed No 3 (+) 1 IV TPC (TC) I
19 15 Mixed breed No 1 (-) 0 I TPC (PC) I
20 8 Poodle No 2 (-) 0 II TPC (CPC) ND
21 11 Mixed breed No 1 (-) 0 I TPC (TC) I
22 13 Mixed breed No 3 (-) ND III TPC (CPC) I
23 13 Mixed breed No 2 (-) 0 II TPC (TC) ND
24 11 Poodle No 3 ND 0 III TPC (CPC) II
25 15 Mixed breed Yes 3 (-) 0 III TPC (CPC) I
26 7 Mixed breed No 3 (-) 0 III TPC ND
27 11 Mixed breed Yes 3 (-) 1 IV TPC I
28 2 Mixed breed Yes 2 (-) 0 II SC ND
29 13 Irish setter No 3 (-) 0 III TPC (TC) I
30 14 Mixed breed Yes 3 (-) 0 III TPC III
31 8 English Cocker Spaniel No 3 (-) 0 III TPC (CPC) ND
32 8 Poodle No 2 (-) 0 II TPC I
33 8 Poodle No 2 (-) 0 II TPC (CPC) I
34 10 Poodle Yes 2 (-) 1 IV TPC I
35 9 Rottweiler Yes 2 (-) 0 II TPC (TC) I
36 7 Mixed breed No 2 (-) 0 II TPC (CPC) ND
37 7 Akita No 2 (+) 1 IV TPC III
38 13 Mixed breed No 1 (-) 0 I TPC (TC) II
Clinical stage classification, according to Owen [23]. Tumor types: complex carcinoma (CC); tubulopapillary carcinoma (TPC), subdivided in tubular 
carcinoma (TC), papillary carcinoma (PC) and cystic-papillary carcinoma (CPC); and solid carcinoma (SC), according to Misdorp et al., [24]. 
Histological grade, according to Elston & Ellis [33]. ND: not determined; (-): absent; (+): present.Acta Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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0.3–0.4 mm-thick slices, using the Krumdieck tissue slicer
(Alabama Research and Development Corporation, Bir-
mingham, AL, USA) [20]. Four to six tumor slices were
then cultured into two Petri dishes (90 × 15 mm), one
containing just culture medium (10 mL RPMI, supple-
mented with 10% bovine fetal serum and 100 U/mL amp-
icillin, 100 mg/mL streptomycin) and the other one, also
containing doxorubicin (1 μM) at 37°C in a humidified
atmosphere of 95% air, 5% CO2, for 24 h. After the treat-
ment period, one slice of tissue was fixed in buffered for-
malin for histological analysis and cell counting and the
other slices were cryopreserved in liquid nitrogen for
molecular analysis. Infiltrative cancer was represented on
all samples analyzed as verified by histological analysis.
Response was evaluated by cell counting in paraffin
embedded and hematoxilin-eosin stained slides of
untreated (control) and corresponding doxorubicin
treated tissue specimens (Figure 1). For this examination
ten circles of 2 mm diameter were randomly drawn over
the glass slides and encircled tumor cells were counted,
using a Nikon Eclipse E-600 microscope (Nikon Instru-
ments Inc, Melville, NY, USA).
At first, 16 samples had their cell number counted by two
observers (RS and STH), to establish the inter-observer
variation. Both observers counted all tumor cells inside
the ten circles, and a mean value was calculated, which
was considered 100% (example, RS: 750 cells and STH:
830 cells, mean 790 cells = 100%). The difference
between cells counted by observers and the mean, was
determined as percentage of variation (ex: difference
observers and mean: 40 cells = 5.0% variation). A positive
correlation was observed between the two observers (r =
0.797,  P  < 0.001, Spearman correlation) and mean,
median and 75 percentage variations in cell counting
between them were 13.8%, 11.75% and 21.7%, respec-
tively.
These calculations were used to establish a cut-off value to
define response to chemotherapy. We assumed that a
reduction in cell number between doxorubicin treated
and control samples superior to the 75 percentage varia-
tion in cell counting by different observers (21.7%) would
be significant. Hence, we have arbitrarily adopted a reduc-
tion of 21.7%, as the cut-off value to define response.
All 38 samples maintained in cell culture and untreated or
treated with doxorubicin had their tumor cells counted.
The difference in tumor cell number between samples was
expressed as percentage of variation [(cell number of
treated sample – cell number of untreated sample) × 100/
cell number of untreated sample]. Responsive samples
were those presenting a reduction in the number of cells
equal or higher than 21.7%, between treated and
untreated samples (Table 2).
Total RNA from frozen specimens
Gene expression was determined in cultured slices not
exposed to doxorubicin, in accordance to our previous
work, in which gene expression was determined in tumor
biopsies, collected before the neoadjuvant treatment [18].
Tissue specimens were pulverized (Bio-Pulverizer™
BioSpec Products Inc., OK, USA) under liquid nitrogen
and total RNA was isolated using Trizol reagent (Invitro-
gen Corporation, Carlsbad, CA, USA), according to the
manufacturer's protocol. All RNA samples were treated
with DNaseI for 30 min at 37°C to eliminate genomic
Specimens maintained in culture medium and unexposed (A)  or exposed (B) to doxorubicin for 24 h Figure 1
Specimens maintained in culture medium and unex-
posed (A) or exposed (B) to doxorubicin for 24 h. 
Mammary gland tissue is well preserved upon culture. Bar = 
10 μm.Acta Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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DNA contamination. RNA quality and integrity was veri-
fied by the Absorbance A260/280, which varied between
1.78 and 2.0, and through observation of 28S/18S rRNA
on agarose gel (1%) electrophoresis in denaturant condi-
tions (ratio > 1.5).
Real-time quantitative reverse transcription-polymerase 
chain reaction
Two micrograms of total RNA was reverse-transcribed
using oligo(dT) primer and Superscript II (Invitrogen).
Real-time (RT)-PCR was performed using SYBR-green I
(Sigma, St. Louis, MO, USA) in a Rotor-gene system (Cor-
bett Research, Mortlake, Australia).
PCR primer sets for SYBR-green I RT-PCR were designed
based on the full-length sequences from exons, separated
by introns, preferentially located in the coding region,
closer to the 3' end of the gene (Table 3) using the soft-
ware Primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi. All sequences were specific for Canis
lupus familiaris.
Amplification reactions were carried out using 2 μL cDNA
diluted 1:10 (final volume of 20 μL), 1.25 units Platinum
Taq Polymerase (Invitrogen), 1× polymerase buffer (Inv-
itrogen), 2.0 mM MgCl2, 200 μM each dNTP, 0.2 μM each
primer, 5% DMSO, 0.5 μL BSA 10 mg/mL (Promega
Table 2: Tumor response to doxorubicin in vitro treatment.
Patient Cell number in control samples Cell number in treated samples Cell number variation (%) Response
1 2307 1543 - 33,12 R
2 335 297 - 11,34 NR
3 2611 2472 - 5,32 NR
4 2800 2575 - 8,04 NR
5 472 216 - 54,24 R
6 445 278 - 37,53 R
7 354 304 - 14,12 NR
8 1339 1412 + 5,45 NR
9 1581 1337 - 15,43 NR
10 1405 625 - 55,52 R
11 644 656 + 1,86 NR
12 699 700 + 0,14 NR
13 5414 5086 - 6,06 NR
14 2816 2602 - 7,60 NR
15 1268 1095 - 13,64 NR
16 1851 1644 - 11,18 NR
17 11189 9691 - 13,39 NR
18 4964 3713 - 25,20 R
19 1047 1031 - 1,53 NR
20 1869 1656 - 11,40 NR
21 1629 1199 - 26,40 R
22 1675 1234 - 26,33 R
23 1879 1722 - 8,36 NR
24 2155 2103 - 2,41 NR
25 668 576 - 13,77 NR
26 4849 4262 - 12,11 NR
27 3329 3266 - 1,89 NR
28 4376 3396 - 22,39 R
29 3559 2863 - 19,56 NR
30 2716 2932 + 7,95 NR
31 4605 3569 - 22,50 R
32 5025 4242 - 15,58 NR
33 4239 4147 - 2,17 NR
34 4334 4146 - 4,34 NR
35 3691 4131 + 11,92 NR
36 5841 4659 - 20,24 NR
37 2201 2256 + 2,50 NR
38 5578 4533 - 18,73 NR
Cell number was counted in control (untreated) and doxorubicin treated samples. The signal (-) stands for the percentage cell reduction and (+) for 
the percentage cell increase, in treated as compared to control samples. R: responsive (reduction in cell number ≥ 21.7%); NR: non-responsive 
(reduction < 21.7%).Acta Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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Corp., Madison, WI, USA), and 0.1 μL SYBR®  Green.
Amplification conditions consisted of denaturation at
95°C for 15 s followed by 40 cycles for annealing at 60°C
for 60 s, and extension at 72°C for 60 s.
Relative expression of the genes of interest was calculated
based on the expression of the endogenous housekeeping
gene GAPDH. A pool of six samples from canine mam-
mary tissue, collected from a mammary gland far away
from the primary tumor site and not affected by any kind
of tumor, was considered as a reference sample in all
determinations. Reactions were performed in duplicate
and CT variation between them was < 1.5. Analysis was
performed as recommended by Pfaffl [25] using the effi-
ciency value of the reaction and the CT value.
Relative expression results were then transformed to their
natural logarithm values. Tumor specimens were then
spatially disposed according to the expression of trios of
genes. Fisher linear discrimination test was used to gener-
ate a separation plane between responsive and non-
responsive samples.
Results
Based on the previous established response criterion, a
reduction in the cell number ≥ 21.7% upon doxorubicin
treatment, nine samples were considered responsive to
doxorubicin and 29 non-responsive (Table 2). In addi-
tion, considering the 38 samples treated and untreated, a
mean reduction of 13.6% in the cell number (P < 0.001,
Mann-Whitney test) was observed upon treatment.
Expression of PRSS11, MTSS1, CLPTM1 and SMYD2 was
determined in tumor samples. Distribution of samples
according to the expression of two trios of genes PRSS11,
MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2, was then
verified, in an attempt to separate responsive from non-
responsive tumors. However, we could not verify a clear
separation of tumors according to response to treatment
(Figure 2).
As we adopted a very strict parameter to consider response
to treatment (cell reduction ≥ 21.7%), we have also deter-
mined gene expression, considering the median percent-
age variation of cell counting between observers (11.7%)
as the cut-off value of drug response. Using this parame-
ter, 18 samples would be considered responsive and 20
non-responsive. However, three dimension distribution
of samples based on the expression of the same two trios
of genes could not separate tumors, according to response
to doxorubicin (data not shown).
Discussion
Tumor slices cultured in vitro may be an interesting model
to evaluate drug response as it preserves some of the in vivo
characteristics, as the epithelial mesenchymal relation-
ship. An important issue is to guarantee a proper diffusion
of oxygen and nutrients to the entire slice, as passive dif-
fusion occurs through only 200 μm. In our study, tumor
thickness varied between 300–400 μm and each tumor
slice was placed on wells filled with culture medium,
allowing them to float; conditions which, were previously
shown to be appropriate to organ culture [19-22].
Slices were exposed to doxorubicin at a concentration of 1
μM, which equals the therapeutic dose in dogs. In addi-
tion, a similar concentration (0.84 μM) was shown to be
the 50% inhibitory concentration in cell culture of mam-
mary gland tumors, obtained from dogs [12]. Hence, an
appropriate drug concentration for dogs was used.
In the present study, nine of 38 samples (23.6%) were
classified as responsive to treatment. This response rate
was inferior to that observed in women with breast cancer,
submitted to neoadjuvant chemotherapy consisting of 4
cycles of anthracyclines, whose objective clinical response
may vary between 49 and 85% [13,15,26]. Partial clinical
response is defined as a tumor reduction ≥ 30%, evaluated
by tumor dimension, according to RECIST criteria [17].
However, the high clinical response rate (49–85%) was
observed after four cycles of neoadjuvant treatment,
Table 3: Primer sequences of genes of interest. Sequences were obtained from Canis lupus familiaris.
Gene GenBank Accession number primer sequence Product size
PRSS11 XM_535044 Sense TGCTTTCGGAGCGTATATC 159 bp
Anti-sense CCATGTTCAGGGTGTTCTCC
MTSS1 XM_539158 Sense GACTCCCTTCAGTGCTCCAG 189 bp
Anti-sense CCGGTAAGACTGGCTGATGT
CLPTM1 XM_541570 Sense TGAGGGCCTTGTAAGTGAGC 151 bp
Anti-sense CACAAGGGCTGGTACTCCTG
SMYD2 XM_537149 Sense GCTTGTACATGCAGGACTGG 202 bp
Anti-sense CCGTGAGCCACTTCCATTAT
GAPDH NM_001003142 Sense GGGTCATCATCTCTGCTCCT 150 bp
Anti-sense AGTGGTCATGGATGACTTTGGActa Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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Three-dimensional distribution of tumor samples according to expression of three genes: (a) PRSS11, MTSS1, CLPTM1 and (b)  PRSS11, MTSS1, SMYD2 Figure 2
Three-dimensional distribution of tumor samples according to expression of three genes: (a) PRSS11, MTSS1, 
CLPTM1 and (b) PRSS11, MTSS1, SMYD2. Tumor response was defined as a reduction in cell number ≥ 21,7%. Each 
tumor is represented by a signal: green cross (non-responsive tumors, N = 29), red cross (responsive tumors, N = 9). Relative 
gene expression is shown on the axis as its natural logarithm value. Fisher linear discrimination test was used to generate a sep-
aration plane represented in blue.Acta Veterinaria Scandinavica 2008, 50:27 http://www.actavetscand.com/content/50/1/27
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whether a low rate (23.6%), as we have observed, might
reflect a single 24 h exposure.
Another aspect to take into consideration is the tumor his-
tological grade. In women, increased clinical response
rates were associated with high histological grade [27,28].
The histological grade seems to be of prognostic value in
canine mammary carcinoma patients as in human
patients [29]. However, in the present series, 47% of the
tumors were low grade, which may have contributed to a
low response rate.
Clinical response measured as a reduction in tumor
dimension reflects a decrease in tumor cell number. We
observed a mean reduction of 13.6% on the cell number
and, in accordance to our data, Ciftci et al. [30] observed
a reduction between 12–16% while analyzing human
breast normal epithelial (MCF10) and cancer lineages
(MCF7, MDA) using the same concentration of doxoru-
bicin. Thus, we believe that the results of our study reflect
an initial response after a short period treatment.
In the present series, the expression of trios of genes
MTSS1, PRSS11, CLPTM1 and MTSS1, PRSS11, SMYD2,
could not cluster canine samples according to response to
doxorubicin. Recent studies indicate that tumors with
diverse prognosis present a characteristic gene expression.
According to this hypothesis, the primary tumor expres-
sion profile may identify patients with an indolent disease
from those with an aggressive disease [31,32]. Our previ-
ous study in breast cancer patients treated with neoadju-
vant AC included mainly women with advanced disease.
Comparing tumor grades in different species is not
straight forward as clinical stage criteria differ between
animal species. However a certain level of comparison is
possible. In the present series, 39% of the dogs presented
in clinical stage III, 5% had lymph node metastasis and
13% presented pulmonary metastasis, as compared to
80%, 75% and none, respectively, considering the women
patients [18]. Hence, as clinical stage is a powerful prog-
nostic factor and as tumor transcriptome varies among
tumors with differential prognosis [31,32], it could be
inferred that early and advanced stage tumors present a
differential gene expression profile associated with doxo-
rubicin response. Furthermore, in our current work, inva-
sive tubular adenocarcinoma and invasive solid
carcinoma, which are associated with a poor prognosis
[1,33] represented 43% of the specimens, and these histo-
logical types might have been an adequate model to study
aggressive tumors in dogs. Finally, inter-species genetic
heterogeneity is another factor that could have contrib-
uted to determine a diverse gene expression associated
with response to chemotherapy.
It is important to emphasize that an ex-vivo model of tis-
sue slice culture, where epithelial-mesenchymal interac-
tions are maintained, may add information to a model
where isolated cells are cultured. In addition, an ex-vivo
model allows a closer evaluation of cell heterogeneity
associated with each individual tumor. However,
although this model may be useful to study some aspects
underlying chemotherapy response, conclusive data on
predictive factors deserves further validation through clin-
ical studies where patients receive chemotherapy.
Conclusion
Our data suggest that short term culture of mammary
tumor slices seems to be an interesting model to evaluate
doxorubicin activity. However, parallel comparisons
between in vitro and in vivo drug responses to establish
their exact correlation are needed. Moreover, our results
on the expression of a few genes emphasize the need to
obtain a more detailed gene expression profile, associated
with chemotherapy response in canine tumors.
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